Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 15, 2018
Pharmacy Choice - Pharmaceutical News - Artemis Therapeutics Receives Orphan Drug Designation From U.S. Food And Drug Administration For Artemisone For The Treatment Of Malaria - October 15, 2018

Pharmacy News Article

 11/20/17 - Artemis Therapeutics Receives Orphan Drug Designation From U.S. Food And Drug Administration For Artemisone For The Treatment Of Malaria

By a News Reporter-Staff News Editor at Pharma Business Week Artemis Therapeutics, Inc. (OTCQB: ATMS), ("Artemis" or the "Company"), a pharmaceutical company developing new therapies for the treatment of life-threatening infectious diseases, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for Artemisone, the Company's lead product candidate, for the treatment of malaria (see also Artemis Therapeutics, Inc.).

"We are delighted Artemisone has received orphan drug designation from the FDA for the treatment of malaria," stated Brian M. Culley, Chief Executive Officer of Artemis. "With approximately half of the world's population at risk, malaria presents an unmet global challenge with enormous economic implications. In recent years, artemisinin-resistant malaria has become increasingly common. Our product candidate, Artemisone, is a potent and fast-acting member of the artemisinin class and we believe it may offer a more attractive safety and efficacy profile compared to currently-available artemisinins. We are excited to be moving Artemisone toward additional clinical trials."

The FDA Orphan Drug designation program provides incentives to sponsors that are developing therapies for rare diseases which affect fewer than 200,000 people in the United States. Artemis is now qualified to receive significant benefits throughout its orphan drug development program including more frequent FDA interactions, protocol assistance, and tax credits for clinical research costs. Also included is a waiver of certain fees and a seven-year term of market exclusivity upon FDA approval of the orphan drug. In 2015, malaria caused 212 million clinical episodes and 429,000 deaths, according to the World Health Organization.

Keywords for this news article include: Malaria, FDA Actions, Regulatory Agencies, Protozoan Infections, Mosquito-Borne Diseases, Artemis Therapeutics Inc., Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 16: Management of Alcohol Use Disorders
Last Chance
Oct 17: Telepharmacy- Remote Delivery of Pharmacy Services
Oct 18: Obesity Management: Overview of Pharmacotherapy
Oct 22: An Integrative Approach to Managing Arthritis
Oct 23: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement